Incyte and Genesis will leverage Genesis’ GEMS artificial intelligence (AI) platform to unlock the discovery of breakthrough small molecule therapeutics against Incyte-selected targets
Incyte and Genesis Therapeutics, Inc. announced that the companies have entered into a strategic collaboration focused on the research, discovery and development of novel small molecule medicines, with an initial focus on collaboration targets selected by Incyte.
Genesis is pioneering generative and predictive artificial intelligence (AI) technologies to help create therapeutics for challenging targets. Utilizing Genesis’ proprietary AI platform, GEMS (Genesis Exploration of Molecular Space), the partnership will pursue the discovery and optimization of small molecule compounds for the collaboration targets. Incyte is granted exclusive rights for potential clinical development and commercialization of collaboration products.
Also Read: COEPTIS NexGenAI & MarketLeverage Partner for AI Marketing
“As a leader in pharmaceutical innovation, Incyte is continually seeking new technologies that can transform how new medicines are discovered and developed,” said Pablo J. Cagnoni, M.D., President and Head of Research and Development at Incyte. “Partnering with Genesis Therapeutics presents a unique opportunity to leverage their AI technologies to accelerate the discovery of breakthrough small molecules for high-impact targets in our pipeline.”
“AI has the potential to redefine how we discover small molecule medicines, and our team is at the forefront of this revolution,” said Evan Feinberg, Ph.D., Founder and Chief Executive Officer of Genesis. “We are pleased to establish this world-class partnership to combine our GEMS AI platform with Incyte’s deep expertise and track record in drug discovery and development, with the shared goal of advancing critical treatments for patients with severe diseases.”
Source: Businesswire